Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Canada: Expected healthy double-digit to mid-teens growth post-acquisition absorption; like-for-like growth ~25% in Q3; targeting mid-teens growth going forward. Emcure targets continued strong growth in key international markets: mid-teens growth in Canada post-acquisition, aiming for about 25% like-for-like growth in the recent quarter.
From Emcure Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Canada: Expected healthy double-digit to mid-teens growth post-acquisition absorption; like-for-like growth ~25% in Q3; targeting mid-teens growth going forward.
- Europe: Muted low single-digit growth in current year; targeting high single-digit growth in FY26.
- Emerging Markets (non-ARV): Expected relatively flattish currently; targeting around 20% growth.
- Domestic India: Focus on recovering and growing faster than industry; growth initiatives in derma, ophthalmology, oncology, women's health, diabetes; aim for 50-100 basis points above industry growth.
- Cardio segment: Some current slowdown; expecting improvement and upper growth trajectory from Q4 onwards.
- ARV sales: About half of emerging market sales; filing differentiated products to gain traction.
2 more points from Emcure Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Emcure Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emcure Pharmaceuticals has operationalized four new manufacturing facilities in Pune, Sanand, Mehsana, and Kadu over the last 18 months.
- Pune facility is at peak utilization.
- Sanand plant is about 60% utilized.
- Mehsana has two lines: orals are 50%+ utilized; injectables expected to take 12-18 months to reach optimal utilization.
- Kadu facility is approaching break-even, expected by the fiscal year-end.
- The company plans continued investment in R&D, maintaining 4-5% of revenues spent on biologics, differentiated products, and related innovation.
- Strategic investments include setting up a new Derma subsidiary, Emcutix, with a team of 200 and product launches planned.
2 more points from Emcure Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Emcure Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Emcure Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.5K Cr, net profit ₹244 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Emcure Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Emcure Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q3 FY25 results?
Canada: Expected healthy double-digit to mid-teens growth post-acquisition absorption; like-for-like growth ~25% in Q3; targeting mid-teens growth going forward. Emcure targets continued strong growth in key international markets: mid-teens growth in Canada post-acquisition, aiming for about 25% like-for-like growth in the recent quarter.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
Emcure Pharmaceuticals has operationalized four new manufacturing facilities in Pune, Sanand, Mehsana, and Kadu over the last 18 months.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.